Results 181 to 190 of about 8,539 (209)
Some of the next articles are maybe not open access.
Best Practice & Research Clinical Endocrinology & Metabolism, 2009
This review focus on the epidemiology, diagnosis and treatment of prolactinomas. In particular, attention was given to recent data showing a high prevalence of these tumours in the general population, 3-5 times higher than previously reported. The diagnosis of hyperprolactinaemia has been simplified in recent years, and only prolactin (PRL) assay and ...
openaire +4 more sources
This review focus on the epidemiology, diagnosis and treatment of prolactinomas. In particular, attention was given to recent data showing a high prevalence of these tumours in the general population, 3-5 times higher than previously reported. The diagnosis of hyperprolactinaemia has been simplified in recent years, and only prolactin (PRL) assay and ...
openaire +4 more sources
Annual Review of Medicine, 1989
Prolactinomas are the most common of the hormone-secreting pituitary tumors and must be distinguished from nonsecreting tumors causing hyperprolactinemia by hypothalamic or stalk dysfunction. For both micro- and macroadenomas, dopamine agonists appear to be the treatment of choice, transsphenoidal surgery being reserved for nonresponders.
openaire +3 more sources
Prolactinomas are the most common of the hormone-secreting pituitary tumors and must be distinguished from nonsecreting tumors causing hyperprolactinemia by hypothalamic or stalk dysfunction. For both micro- and macroadenomas, dopamine agonists appear to be the treatment of choice, transsphenoidal surgery being reserved for nonresponders.
openaire +3 more sources
Clinical Endocrinology, 1991
The management of prolactinomas requires a complex interaction of medical, surgical and radiotherapeutic intervention. With the judicious use of all these modalities, patients can usually be managed with great success and, perhaps more importantly, their presenting complaints (gonadal dysfunction and infertility) are usually completely corrected.
David Cunnah, Michael Besser
openaire +3 more sources
The management of prolactinomas requires a complex interaction of medical, surgical and radiotherapeutic intervention. With the judicious use of all these modalities, patients can usually be managed with great success and, perhaps more importantly, their presenting complaints (gonadal dysfunction and infertility) are usually completely corrected.
David Cunnah, Michael Besser
openaire +3 more sources
2017
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention and are an important cause of hypogonadism and infertility. They may also be responsible for mass effects. Nevertheless, prolactinomas are not the only case of hyperprolactinemia: many physiological and pathological conditions (pregnancy, medications ...
Philippe Chanson, Dominique Maiter
openaire +2 more sources
Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical attention and are an important cause of hypogonadism and infertility. They may also be responsible for mass effects. Nevertheless, prolactinomas are not the only case of hyperprolactinemia: many physiological and pathological conditions (pregnancy, medications ...
Philippe Chanson, Dominique Maiter
openaire +2 more sources
Clinical Endocrinology, 1995
SummaryBACKGROUND Apart from the rare association with type I multiple endocrine neoplasia (MEN‐1), familial types of prolactinoma have not been reported.PATIENTS AND MEASUREMENTS Eight hyperprolacti‐naemic patients in four families and 18 of their first and second‐degree relatives (parents, children and grandchildren) were examined.
M, Berezin, A, Karasik
openaire +2 more sources
SummaryBACKGROUND Apart from the rare association with type I multiple endocrine neoplasia (MEN‐1), familial types of prolactinoma have not been reported.PATIENTS AND MEASUREMENTS Eight hyperprolacti‐naemic patients in four families and 18 of their first and second‐degree relatives (parents, children and grandchildren) were examined.
M, Berezin, A, Karasik
openaire +2 more sources
Acta Endocrinologica, 1992
Malignant prolactinoma is a rare entity and only a few cases have been published. The diagnostic criteria and the clinical course remain unclear. We present a case of malignant prolactinoma in a woman with a 30-year duration of the disease. In the terminal stage of the disease the prolactinoma metastasized to the left eye, the prolactin level reaching ...
M, Berezin +4 more
openaire +2 more sources
Malignant prolactinoma is a rare entity and only a few cases have been published. The diagnostic criteria and the clinical course remain unclear. We present a case of malignant prolactinoma in a woman with a 30-year duration of the disease. In the terminal stage of the disease the prolactinoma metastasized to the left eye, the prolactin level reaching ...
M, Berezin +4 more
openaire +2 more sources
The Netherlands journal of medicine, 2010
Prolactinomas are a frequent cause of gonadal dysfunction and infertility, especially in women. Dopamine agonists are first-line therapy and their efficacy in the treatment of prolactinomas is well established. Current challenges related to the management of prolactinomas remain in the recurrence of the disease after withdrawal of dopamine agonists ...
Kars, M. +3 more
openaire +3 more sources
Prolactinomas are a frequent cause of gonadal dysfunction and infertility, especially in women. Dopamine agonists are first-line therapy and their efficacy in the treatment of prolactinomas is well established. Current challenges related to the management of prolactinomas remain in the recurrence of the disease after withdrawal of dopamine agonists ...
Kars, M. +3 more
openaire +3 more sources
Annales d'Endocrinologie, 2007
Surgery is generally used as second-line treatment in prolactinomas. For microprolactinomas, it may be indicated in cases of resistance or intolerance to dopamine agonists or where patients prefer definitive cure to lifelong drug treatment. In highly trained hands, selective adenomectomy results in normalization of prolactin levels in 75-90% of cases ...
M, Jan, H, Dufour, T, Brue, P, Jaquet
openaire +2 more sources
Surgery is generally used as second-line treatment in prolactinomas. For microprolactinomas, it may be indicated in cases of resistance or intolerance to dopamine agonists or where patients prefer definitive cure to lifelong drug treatment. In highly trained hands, selective adenomectomy results in normalization of prolactin levels in 75-90% of cases ...
M, Jan, H, Dufour, T, Brue, P, Jaquet
openaire +2 more sources
New England Journal of Medicine, 1979
The secretion of prolactin is tonically inhibited by the hypothalamus, an effect mediated by the release of a prolactin inhibitory factor into the pituitary blood supply.1 Much newly acquired evidence points to dopamine as the principal inhibitory regulator.2 Specific dopamine-containing nerve tracts in the hypothalamus terminate on the blood vessels ...
openaire +3 more sources
The secretion of prolactin is tonically inhibited by the hypothalamus, an effect mediated by the release of a prolactin inhibitory factor into the pituitary blood supply.1 Much newly acquired evidence points to dopamine as the principal inhibitory regulator.2 Specific dopamine-containing nerve tracts in the hypothalamus terminate on the blood vessels ...
openaire +3 more sources
Journal of Endocrinological Investigation, 2011
Prolactinomas are the most common hormonally active pituitary tumors and are usually successfully treated with dopamine agonists. A small proportion, however, appears not to respond to such treatment and such cases are termed resistant prolactinomas. Resistance is generally defined as failure to achieve normoprolactinemia and inability to induce tumor ...
A. Beckers +4 more
openaire +3 more sources
Prolactinomas are the most common hormonally active pituitary tumors and are usually successfully treated with dopamine agonists. A small proportion, however, appears not to respond to such treatment and such cases are termed resistant prolactinomas. Resistance is generally defined as failure to achieve normoprolactinemia and inability to induce tumor ...
A. Beckers +4 more
openaire +3 more sources